Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Equity Ratio (2019 - 2025)

Allogene Therapeutics' Equity Ratio history spans 7 years, with the latest figure at 0.72 for Q3 2025.

  • For Q3 2025, Equity Ratio fell 8.91% year-over-year to 0.72; the TTM value through Sep 2025 reached 0.72, down 8.91%, while the annual FY2024 figure was 0.77, 3.44% down from the prior year.
  • Equity Ratio for Q3 2025 was 0.72 at Allogene Therapeutics, down from 0.73 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.91 in Q2 2021 and bottomed at 0.72 in Q3 2025.
  • The 5-year median for Equity Ratio is 0.81 (2023), against an average of 0.82.
  • The largest annual shift saw Equity Ratio rose 6.67% in 2021 before it fell 10.59% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.88 in 2021, then decreased by 7.81% to 0.81 in 2022, then decreased by 1.83% to 0.8 in 2023, then fell by 3.44% to 0.77 in 2024, then fell by 6.81% to 0.72 in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Equity Ratio are 0.72 (Q3 2025), 0.73 (Q2 2025), and 0.76 (Q1 2025).